Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for patients with hepatoblastoma

Alexander A. Boucher, Tomoyuki Mizuno, Alexander A. Vinks, Stuart L. Goldstein, Greg M. Tiao, James I. Geller

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Hepatoblastoma can be associated with chronic kidney disease and genitourinary anomalies. Cisplatin is a key agent for treating hepatoblastoma but renal clearance and toxicity can limit its use in end-stage renal disease. We present pharmacokinetic data and clinical outcomes using cisplatin on hemodialysis for three patients with hepatoblastoma. All patients were initially treated with surgery and adjuvant cisplatin [1.67 mg/kg (2 patients) or 50 mg/m2 (1 patient)]. The patient treated with body surface area-based dosing had higher exposures and ototoxicity. Treating hepatoblastoma with cisplatin on hemodialysis using 1.67 mg/kg achieved clinical efficacy with minimal morbidity.

Original languageEnglish (US)
Article numbere27425
JournalPediatric Blood and Cancer
Volume66
Issue number1
DOIs
StatePublished - Jan 2019
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018 Wiley Periodicals, Inc.

Keywords

  • cisplatin
  • hemodialysis
  • hepatoblastoma
  • pediatric oncology
  • pharmacokinetics

Fingerprint

Dive into the research topics of 'Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for patients with hepatoblastoma'. Together they form a unique fingerprint.

Cite this